Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Long-term Debt

Borrowings due after more than one year.

Vicore Pharma Holding ABNASDAQ: VCRE

Long-term Debt · Q2 FY2026 · quarter ended Jun 2026

Long-term debt of SEK 0 in Q2 FY2026

Q2 FY2026 long-term debt was SEK 0.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 0— QoQ
Last fiscal yearDec 2025
SEK 0— YoY
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

SEK · from the balance sheet

Latest · FY2025
0 SEK
Year-over-year change
—

Long-term Debt vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Long-term debt amounts to 0.0% of total assets for VCRE, versus a peer median of 23.4%.
VCRE Competitors
Long-term Debt for VCRE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LQDALiquidia CorporationJun 2026$122.15M USD-18.3%+88.4%23.4%
VCREVicore Pharma Holding ABJun 2026SEK 0 SEK——0.0%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —-18.3%+88.4%23.4%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.